Literature DB >> 31212299

Decreased Circulating Levels of Asprosin in Obese Children.

Wenjun Long1, Xuemei Xie2, Caiqi Du3, Yue Zhao3, Cai Zhang3, Di Zhan3, Zhuxi Li3, Qin Ning4, Xiaoping Luo3.   

Abstract

BACKGROUND: Circulating asprosin is a newly discovered adipokine that triggers the release of hepatic glucose stores and increases appetite. Asprosin levels are elevated in adult obese men as well as in mice, and reductions in asprosin protect against the hyperinsulinism associated with metabolic syndrome in mice with diet-induced obesity, which indicates a potential therapeutic role of asprosin in obesity and type 2 diabetes.
OBJECTIVES: Few data on asprosin in children are available, which is why this study aimed to assess concentrations of fasting asprosin, as well as its relationship to parameters of glucose and lipid metabolism, in children.
METHODS: Data on clinical and metabolic parameters were collected from 40 healthy normal-weight and 47 obese children. Circulating asprosin levels were measured using an ELISA.
RESULTS: The concentrations of fasting asprosin were lower in the obese children (9.24 ± 4.11 ng/mL) than in the normal-weight controls (12.33 ± 4.18 ng/mL, p < 0.001). When comparing the two groups by sex, both the boys and the girls showed similar trends. In within-group comparison, the asprosin levels were lower in boys than in girls only in the obese group (8.13 ± 4.10 vs. 10.61 ± 3.78 ng/mL, p = 0.013) but not in the control group. Interestingly, asprosin was correlated with ALT after adjusting for age and sex in all participants; in boys, asprosin was correlated with BMI, HOMA-IR, insulin, and HDL after adjusting for age.
CONCLUSIONS: Concentrations of asprosin were significantly lower in obese children than in normal-weight children, and there was a gender difference in asprosin concentration. Our results suggest a complex role for asprosin in energy metabolism.
© 2019 S. Karger AG, Basel.

Entities:  

Keywords:  Adipokine; Asprosin; Childhood obesity; Energy metabolism

Year:  2019        PMID: 31212299     DOI: 10.1159/000500523

Source DB:  PubMed          Journal:  Horm Res Paediatr        ISSN: 1663-2818            Impact factor:   2.852


  18 in total

1.  Increased plasma asprosin levels in patients with drug-naive anorexia nervosa.

Authors:  Yanran Hu; Yixiang Xu; Yuchen Zheng; Qing Kang; Zhongze Lou; Qiang Liu; Han Chen; Yunxin Ji; Lei Guo; Chen Chen; Liemin Ruan; Jue Chen
Journal:  Eat Weight Disord       Date:  2020-02-05       Impact factor: 4.652

Review 2.  Asprosin, a C-Terminal Cleavage Product of Fibrillin 1 Encoded by the FBN1 Gene, in Health and Disease.

Authors:  Mehmet Akif Ovali; Ibrahim Bozgeyik
Journal:  Mol Syndromol       Date:  2022-02-08

3.  Association of cord blood asprosin concentration with atherogenic lipid profile and anthropometric indices.

Authors:  Hanan Khudhair Hussein; Nassrin Malik Aubead; Hamzah H Kzar; Yasir Salam Karim; Ali H Amin; Moaed E Al-Gazally; Tousief Irshad Ahmed; Mohammed Abed Jawad; Ali Thaeer Hammid; Abduladheem Turki Jalil; Yasser Fakri Mustafa; Marwan Mahmood Saleh; Hafez Heydari
Journal:  Diabetol Metab Syndr       Date:  2022-05-18       Impact factor: 5.395

4.  Serum Asprosin Concentrations in Children with Prader-Willi Syndrome: Correlations with Metabolic Parameters.

Authors:  Maha Alsaif; Catherine J Field; Eloisa Colin-Ramirez; Carla M Prado; Andrea M Haqq
Journal:  J Clin Med       Date:  2022-04-18       Impact factor: 4.964

Review 5.  Energy Regulation Mechanism and Therapeutic Potential of Asprosin.

Authors:  Jennifer G Hoffmann; Wei Xie; Atul R Chopra
Journal:  Diabetes       Date:  2020-04       Impact factor: 9.461

6.  [Expression, purification and functional assessment of asprosin inclusion body].

Authors:  Xuejing Wei; Qingqing Ao; Ling Meng; Yilu Xu; Cailing Lu; Shen Tang; Xinhang Wang; Xiyi Li
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2020-01-30

7.  Decreased Blood Asprosin in Hyperglycemic Menopausal Women as a Result of Whole-Body Cryotherapy Regardless of Metabolic Syndrome.

Authors:  Magdalena Wiecek; Jadwiga Szymura; Justyna Sproull; Zbigniew Szygula
Journal:  J Clin Med       Date:  2019-09-10       Impact factor: 4.241

Review 8.  A state of the art review on the novel mediator asprosin in the metabolic syndrome.

Authors:  Carla Luís; Rúben Fernandes; Raquel Soares; Pedro von Hafe
Journal:  Porto Biomed J       Date:  2020-12-10

Review 9.  Asprosin: A Novel Player in Metabolic Diseases.

Authors:  Mingyang Yuan; Weidong Li; Yan Zhu; Boyao Yu; Jing Wu
Journal:  Front Endocrinol (Lausanne)       Date:  2020-02-19       Impact factor: 5.555

10.  The central melanocortin system and human obesity.

Authors:  Yongjie Yang; Yong Xu
Journal:  J Mol Cell Biol       Date:  2020-10-01       Impact factor: 6.216

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.